RNAC

Cartesian TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$18.00

+117.9% vs current

Most likely

Base case

50%

Probability

Target price

$9.50

+15.0% vs current

B-

Bear case

30%

Probability

Target price

$4.00

-51.6% vs current

AI sentiment snapshot

Latest data as of 2026-07-16

AI commentary

Primary-source support is strong for financing and clinical-program updates, but coverage is low, recent news flow is sparse, social data are unavailable, analyst-target breadth is undisclosed, and no direct operating peer set was validated. The stock remains a cautious monitoring situation with most investable variance concentrated in 2027 clinical outcomes.

RankAlpha Sentiment Codex - 2026-07-16

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-05-26catalystRunway extension reduces near-term financing pressureHigh impact

Cartesian secured an up-to-$150 million non-dilutive facility, including an initial $50 million tranche, and expects cash resources to support planned operations into 2028 [#PR-EARNINGS-2026-05-26].

2027-03-31eventPhase 3 AURORA topline dataHigh impact

Enrollment is progressing in the Phase 3 AURORA trial of Descartes-08 in myasthenia gravis; topline data are expected in the first quarter of 2027 [#SEC-8K-2026-04-30] [#PR-EARNINGS-2026-05-26].

2027-06-30catalystTRITON and HELIOS clinical readoutsHigh impact

TRITON was initiated in myositis and HELIOS has enrolled multiple pediatric patients; company guidance indicates data from both programs in the first half of 2027 [#SEC-8K-2026-04-30] [#PR-EARNINGS-2026-05-26].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-16 • Updated nightlySource: Internal modelMethodology